Workflow
微创外科
icon
Search documents
剥离房地产业务后,厦门国贸转型康养科技:聚焦微创外科,协同发展养老健康服务
Cai Jing Wang· 2025-10-09 10:44
在新的发展阶段,主业为批发零售的厦门国贸在剥离房地产业务后,开始通过并购等方式加速布局康养 科技赛道。 与此同时,作为厦门国贸积极培育和拓展的新兴业务,健康科技业务以创新投资为驱动,通过创新发展 模式整合资源,加速产业布局。 上半年营收净利双降,供应链支柱产业毛利率仅1.26% 近日,厦门国贸在互动平台向投资者表示,公司健康科技业务板块聚焦医疗器械核心主业,协同养老服 务、医疗健康大数据和健康服务等产业展开业务布局。 作为国有控股上市公司,厦门国贸所属行业为批发和零售贸易业中的批发业,主要从事供应链管理业 务、健康科技业务等,公司于1996年10月在上交所挂牌上市。 受多重因素影响,厦门国贸最新业绩并不亮眼。2025年上半年,厦门国贸实现营收1516.58亿元,同比 下降22.31%;实现归母净利润5.23亿元,同比下降37.62%。 其中,健康科技业务板块的医疗器械业务以"上游+中游"双轮驱动策略,大力发展医疗器械核心子赛道 业务,上游加大收并购和战略性投资力度;中游聚焦医疗耗材SPD及配送分销业务,打造供应链服务平 台;养老服务、健康大数据、健康服务深化业务协同,探索医康养智能一体化。 《财经新康养》注意 ...
中国援巴新医疗队举办微创外科培训
Xin Hua She· 2025-09-26 09:04
Core Points - The 14th Chinese medical team in Papua New Guinea (PNG) held a minimally invasive surgery training session and academic forum, aimed at enhancing local surgical capabilities [1] - The project has been a significant milestone in the development of the Port Moresby General Hospital, with improvements in surgical volume, treatment outcomes, and skills of medical staff [1][2] - The Chinese medical team emphasizes the importance of training and knowledge transfer, aiming to establish advanced minimally invasive techniques in PNG for the benefit of more patients [1] Group 1 - The training session included specialized lectures on urology and breast tumor surgery, attended by over 20 local doctors and nurses [1] - The project has been active since 2018, covering multiple disciplines such as urology, general surgery, gynecology, breast surgery, and neurosurgery [2] - The local hospital director highlighted the collaboration between Chinese and PNG medical personnel, which is providing safer and more effective treatment options for patients [1] Group 2 - The Chinese medical team also introduced the progress of traditional Chinese medicine acupuncture training, awarding certificates to five local physicians who completed the course [1]
全球微创外科器械市场规模持续扩大,迈瑞医疗微创外科业务高速增长
Jiang Nan Shi Bao· 2025-09-15 08:37
Core Insights - The company has revealed significant growth in its three high-potential business segments: minimally invasive surgery, animal healthcare, and cardiovascular, with a combined revenue exceeding 4 billion yuan in 2024, accounting for over 10% of total revenue and growing at rates above 25% [1] Group 1: Minimally Invasive Surgery - The minimally invasive surgery segment has shown remarkable performance, achieving over 10% market share for its hard mirror system, ranking just behind two imported brands, and is expected to increase its market share rapidly due to its advanced product offerings [2] - The total addressable market for minimally invasive surgery in China exceeds 200 billion yuan, with high-value consumables, particularly ultrasonic knives and laparoscopic staplers, representing a combined market capacity of over 110 billion yuan, currently dominated by two foreign brands [2] - The company has successfully entered multiple procurement projects in regions such as Beijing-Tianjin-Hebei and Fujian, and is investing in building a specialized sales team to accelerate the growth of its consumable business [2] Group 2: Market Environment and Growth Potential - The global market for minimally invasive surgical instruments is expanding steadily, with a significant gap in the penetration rate of minimally invasive surgeries between China (14% in 2021) and the United States (over 50% in the same year), indicating substantial unmet clinical demand in China [2] - The number of minimally invasive surgeries in China reached 12.53 million in 2022, with projections estimating it will grow to approximately 20.95 million by 2025 and further to about 34.23 million by 2030, reflecting a compound annual growth rate of 10.3% [2] - 2025 is anticipated to be a pivotal year for the domestic market growth of high-value consumables such as ultrasonic knives and staplers, which will provide strong momentum for the company's long-term growth in life information and support business [3] Group 3: Synergy and Future Outlook - The minimally invasive surgery products create a synergistic effect with the company's traditional product lines, allowing for integrated solutions that enhance product value and customer loyalty [3] - Continued expansion of the product line and further clinical application promotion are expected to sustain rapid growth in the minimally invasive surgery business, contributing to new revenue streams and enhancing overall competitiveness [3]
占全市近40%!北京亦庄外资研发中心突破100家
Xin Jing Bao· 2025-08-12 08:51
Core Insights - The recent announcement by Beijing Municipal Science and Technology Commission and Zhongguancun Science Park Management Committee recognized 20 companies, including Anhe Gallier Technology Co., Ltd. and Alter Automotive Technology Co., Ltd., as foreign-funded R&D centers, highlighting the leading position of Beijing Economic-Technological Development Area in technological innovation [1] - The total number of recognized foreign-funded R&D centers in Beijing Yizhuang has reached 109, accounting for nearly 40% of the city's total, indicating a significant contribution to high-quality regional development [1] Company Highlights - Alter, the first independent automotive design company listed in China, has demonstrated strong innovation capabilities through breakthroughs in smart chassis technology and advanced powertrains, positioning itself among the recognized foreign-funded R&D centers [2] - Alter's smart digital chassis platform integrates several cutting-edge technologies, supporting high-level assisted driving, and its innovative electromagnetic DHT and integrated VCU and MCU power domain controller are leading trends in the automotive industry [2] - Anhe Gallier, a medical technology company focused on ultrasonic surgical knives, aims to break the monopoly of international giants in core technologies through its newly recognized foreign-funded R&D center, particularly in key areas like rod materials and transducer frequency stability [3] - Anhe Gallier's ultrasonic surgical knife system has achieved domestic market penetration, breaking the long-standing dominance of imported brands, and aims to become a global leader in minimally invasive surgical equipment through technological innovation and product upgrades [3] Regional Development - The recognition of these companies is a testament to their innovation capabilities and reflects the continuous optimization of the innovation ecosystem in Beijing Economic-Technological Development Area [4] - The area has established a comprehensive policy service system covering talent introduction, tax incentives, and intellectual property protection to support the construction of foreign-funded R&D centers [4] - Future plans include further optimizing the business environment and providing lifecycle services for foreign-funded R&D centers, positioning Beijing Economic-Technological Development Area as a key hub for global innovation elements [4]
获批上市!一次性使用腹壁穿刺缝合器
思宇MedTech· 2025-03-02 14:47
常州海尔斯医疗器械科技有限公司 发明的专利产品 一次性使用腹壁穿刺缝合器 已获批上市 ,该产品用于腹腔镜手术中为内窥镜器械提供通道,并 用于闭合穿刺通道筋膜及切口。 这是一种 融合了腹壁穿刺功能及缝合功能 的创新型产品 ,为微创手术造成的切口疝提供了有效的解决方案。 近年来,具有创伤小、恢复快、治愈率高等优点的微创外科发展迅速, 但术后缝合时,腹壁筋膜缝合有较大难度,缝合效果不理想,容易发生切口 疝,穿刺孔切口疝的发病率为0.5-5%左右 ,这一问题给广大外科医生造成了极大的困扰。 因此,为了解决这一临床手术中的难题,针对性地开发了这款全新一代"一次性使用腹壁穿刺缝合器",其将筋膜缝合器与穿刺器"双剑合璧", 关闭 筋膜成功率近乎100%,能够显著降低切口疝的发生,节约手术时间 。 其具有下列优点: 这一创新型产品具有现实的意义,是解决切口疝问题非常有效的方法,为医生提供了一种安全、有效和快速的切口关闭方案。原理简单易懂,操作便 捷,对医生的经验要求没那么高,医生学习曲线很短,能够快速地推广。 ---解放军总医院 夏教授 是临床急需的非常实用的产品,它解决了完整微创手术的"最后一公里"。 ---山东省立医院 ...